Trends in Utilization, Spending, and Prices of Smoking-Cessation Medications in Medicaid Programs: 25 Years Empirical Data Analysis, 1991-2015
Part of this information was presented as a poster at the 2016 Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
The Importance and Benefits of Smoking-Cessation Therapy
Comparing the Medicaid Retrospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies
The Medicaid Drug Utilization Review (DUR) program promotes patient safety through state-administered drug utilization management tools and systems.
Is the Federal Drug Utilization Review Requirement Just Red Tape or an Enlightened State of Flexibility?
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights - Regulatory
Washington, DC—A panel discussion on health and drug politics took place at the Sixth Annual Conference of the Association for Value-Based Cancer Care. The expert panel included Kavita Patel, MD, Johns Hopkins Medicine, Baltimore; Dan Todd, Principal of Todd Strategy, Washington, DC; and Liz Fowler, Vice President, Global Health Policy, Johnson & Johnson. The panel discussed what is working in healthcare, what is not, and where cancer care fits into it all.
Examining the Value of Subsidies of Health Plans and Cost-Sharing for Prescription Drugs in the Health Insurance Marketplace
The Affordable Care Act (ACA) initiated health insurance exchanges, or marketplaces, with health plans offering subsidies for plan members, to help individuals, families, and small businesses find health plans that fit their specific needs. By the end of the first open enrollment period, more than 8 million Americans selected qualified health plans through the ACA-initiated health insurance marketplace, and by February 2015, more than 10 million people enrolled and paid for health coverage through those plans in these marketplaces. Under state and federal rules and regulations, the ACA allowed insurers to offer a variety of well-defined health insurance plans and compete through the marketplace.
Health Plan Subsidies, Prescription Drugs, and Cost
The cost of cancer care in the United States continues to rise, in part as a result of the aging population and improvements in diagnosis, treatment, and survival. These costs are projected to reach $173 billion in 2020, representing a 39% increase from 2010
Implementing Payment Reform in Oncology: Benefits and Challenges
Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges
Alan L. Shields, PhD, Yanni Hao, PhD, Meaghan Krohe, PhD, Andrew Yaworsky, Iyar Mazar, MA, Catherine Foley, MPH, MA, Faisal Mehmed, MD, Denise Globe, PhD
Junling Wang, PhD, Ya-Chen Tina Shih, PhD, Yolanda Qin, Theo Young, BS, Zachary Thomas, MS, MBA, Christina A. Spivey, PhD, David K. Solomon, BSc, PharmD, Marie Chisholm-Burns, PharmD, MPH, MBA, FCCP, FASHP, J. Warren Salmon, PhD
In a 2013 report, the IMS Institute for Healthcare Informatics estimated that the United States spent more than $213 billion on unnecessary medical expenses as a result of irresponsible medication use.
Is It Time to Revisit Medicare Part D?
Effects of Medicare Part D on Disparity Implications of Medication Therapy Management Eligibility Criteria
Marie Chisholm-Burns, PharmD, MPH, MBA, FCCP, FASHP, William C. Cushman, MD, Samuel Dagogo-Jack, MD, FRCP, JoEllen Jarrett Jamison, BS, Liyuan Li, PhD, Yanru Qiao, MS, Ya-Chen Tina Shih, PhD, Christina A. Spivey, PhD, Jim Y. Wan, PhD, Junling Wang, PhD, Shelley I. White-Means, PhD
Previous studies have shown that there were greater racial and ethnic disparities among individuals who were ineligible for medication therapy management (MTM) services than among MTM-eligible individuals before the implementation of Medicare Part D in 2006.
Medication Therapy Management, Medicare, and Disparities in Population Health
Offering Lung Cancer Screening to High-Risk Medicare Beneficiaries Saves Lives and Is Cost-Effective: An Actuarial Analysis
Ellynne Dec, ASA, MAAA, Claudia I. Henschke, PhD, MD, David F. Yankelevitz, MD, Rowena Yip, MPH, Bruce S. Pyenson, FSA, MAAA
By a wide margin, lung cancer is the most significant cause of cancer death in the United States and worldwide. The incidence of lung cancer increases with age, and Medicare beneficiaries are often at increased risk. Because of its demonstrated effectiveness in reducing mortality, lung cancer screening with low-dose computed tomography (LDCT) imaging will be covered without cost-sharing starting January 1, 2015, by nongrandfathered commercial plans. Medicare is considering coverage for lung cancer screening.
Cost-Effectiveness and the Medicare Budget
Page 1 of 4
Results 1 - 10 of 38
Results 1 - 10 of 38